Diabetes Risk of Olanzapine vs. Aripiprazole in Mental Illness
Author Information
Author(s): Agniel Denis PhD, Normand Sharon-Lise T. PhD, Newcomer John W., Zelevinsky Katya MS, Poulos Jason PhD, Tsuei Jeannette MPhil, Horvitz-Lennon Marcela MD, MPH
Primary Institution: RAND Corporation, Santa Monica, California, USA
Hypothesis
What is the diabetes risk associated with olanzapine compared to aripiprazole in patients with serious mental illnesses?
Conclusion
Aripiprazole is associated with a slightly higher risk of type 2 diabetes compared to olanzapine in patients with serious mental illnesses.
Supporting Evidence
- Aripiprazole-treated patients had fewer diabetes-free months compared to olanzapine-treated patients.
- RMSTs were longer in olanzapine-treated patients across all diagnoses.
- E-values suggest that unobserved confounding is not severe.
Takeaway
This study found that people taking aripiprazole might have a higher chance of getting diabetes than those taking olanzapine.
Methodology
Retrospective cohort study analyzing diabetes risk in adults with schizophrenia, bipolar I disorder, or severe major depressive disorder using administrative billing data.
Potential Biases
Potential for unmeasured confounding due to incomplete clinical information.
Limitations
Unobserved confounding and informative censoring may affect the results.
Participant Demographics
67% White, 50% female, 52% older than 45 years.
Statistical Information
Confidence Interval
[95% CI: 0.14, 0.36]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website